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was calculated. Considering a switch to aztreonam lysine, the reduction of exacerba-
tion was estimated in order to maintain the overall treatment cost. For the base case, 
ex-factory prices were considered; for sensitivity analysis, discounts ranged from 15 
to 50%. Results: Switching to aztreonam lysine would not increase overall treatment 
costs in 8/12 options; even maintaining current exacerbation episodes could lead to 
SNS savings. In the remaining options, the required reduction of exacerbations var-
ies depending on the patient’s current situation, ranging from 110% (one episode/
year) to 18% (six episodes/year). In the sensitivity analysis, there are 3 options in 
which switching to aztreonam lysine would not imply higher treatment costs. For the 
remaining alternatives, the required reduction of exacerbations does not change 
significantly from the base case: from 116% (one episode/year) to 19% (six episodes/
year). ConClusions: In CF patients with chronic pulmonary infection by PA, hos-
pitalizations costs due to exacerbations have a greater economic impact than drug 
treatment costs. Using aztreonam lysine, instead of other treatments, would not imply 
a budget impact in a wide range of patient profiles if exacerbation episodes can be 
reduced. As the number of current exacerbations increases, a lesser reduction of these 
events is required by a switch to aztreonam lysine to avoid incremental treatment costs.
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objeCtives: Meprobamate is a constituent of various combination analgesics in 
South Africa. Due to its abuse potential, the scheduling status of meprobamate is 
currently under review with the possibility of introducing stricter controls on its 
availability. The primary aim was to determine the impact of generic substitution on 
meprobamate-containing combination analgesic prescribing. Methods: A retro-
spective, cross-sectional drug utilisation study was conducted on prescription data 
of a medical insurance scheme administrator in South Africa for 2011. Results: A 
total of 97 491 analgesics were dispensed to 31 854 patients during the year. Within 
ATC category N02B, 62.10% of prescriptions were for analgesic combinations, of 
which 20 326 prescriptions were for meprobamate-containing analgesics at a cost 
of R282 930. A total of 10 404 patients received meprobamate-containing analgesics. 
Overall, 20.85% of all analgesics contained meprobamate. Patients who received 
meprobamate-containing analgesics were slightly older (39.52 years) compared 
to patients who received analgesics in general (33.61 years). Mandatory generic 
substitution exists in South Africa, unless otherwise indicated by the prescriber 
or if the patient refuses. Twenty-two trade names of meprobamate-containing 
analgesics were dispensed, of which 17 (the originator plus 16 branded generics) 
contained exactly the same dosages of active ingredients (320 mg paracetamol, 
8 mg codeine phosphate, 32 mg caffeine and 150 mg meprobamate). In previous 
studies, the originator product was the most often prescribed, yet in this study 
the originator product only constituted 3.72% of products prescribed (average cost: 
R30.42) compared to 70.63% for the most popular branded generic (average cost: 
R11.65). ConClusions: The price difference between generic equivalents and the 
originator product, together with mandatory generic substitution, were responsible 
for the change in prescribing patterns.
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objeCtives: The objective was to estimate the economic burden of B-thalassemia 
and to compare the cost of alternative iron chelation strategies in patients with 
transfusion (TDT) and non-transfusion dependent thalassemias (NTDT) in 
Greece. Methods: A multicenter, non interventional, retrospective, observational, 
phase IV study was conducted in the 3 out of 8 thalassemia units in Attica. Patients’ 
data and resource use, including medication and related consumables, blood trans-
fusions, lab tests, diagnostic examinations and hospital visits were recorded from 
January 2009 to December 2011, and classified per diagnosis and iron chelation treat-
ment strategies. Greek NHS perspective was considered. Results: 331 thalassemic 
patients were recorded whereas the majority (87.6%) was diagnosed with Beta-
thalassemia major, 31% were treated with deferasirox (DFX), 23% with deferoxamine 
and deferiprone, (DFO+DFP), 9.7% with deferiprone (DFP) and 5.1% with DFO. Patient 
mean annual cost per patient was € 32,064, including all treatment strategies, for 
the period 2009-2011, ranging from € 30,997 in 2009 to € 32,564 in 2011. Medication 
(45.9%), blood transfusions (38.1%) and consumables (14.9%) were the most impor-
tant cost drivers. Mean cost per patient treated with DFX was estimated at € 35,928, 
with DFO+DFP at € 34,035, with DFO at € 31,637 and with DFP at € 17,208 for the same 
period. DFX significantly reduced (p< 0.001) the number of blood transfusions in 
relation to DFO+DFP with 19 and 25 transfusions per year, respectively. Similarly, 
DFX significantly reduced the volume of blood transfusions (p< 0.001) in relation 
to DFO with 9,693ml and 10.312ml per year, respectively. ConClusions: Rational 
health care decision making process should be based on the holistic perspective of 
analytical resource use and disease management data rather than focusing on the 
price per product per se. Especially in Greece, a country where Beta-thalassemia 
incidence in general population is ~8 %, the consideration of all cost components 
should be taken into account in health resource allocation.
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frequency of inpatient visits and pulmonary, cardiovascular, renal and skin complica-
tions of SLE in group treated with belimumab. Therefore the use of belimumab led 
to a reduced difference in the required budget funds from 2,118,449 RUB/ 45,581 EUR 
to 1,876,965 RUB/ 40,385 EUR and the reduction ran as high as 241,484 RUB/ 5,196 
EUR for 5 years. ConClusions: The use of belimumab in the treatment of patients 
with SLE resulted in budget spending. However, a good safety profile and efficacy of 
belimumab help reduce the costs for 241,484 RUB/ 5,196 EUR for 5 years in belimumab 
treatment group.
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objeCtives: The aim of the study was to determine public expenditure on medicines 
for rare diseases from the public health sector in the Czech Republic (CZ). Methods: 
We identified orphan medicinal products (OMPs) registered by the European 
Medicines Agency (EMA) until December 2013 in the public database of EMA. In the 
base-case scenario, medicinal products available in the CZ were considered OMPs 
only within the interval of marketing authorisation date and December 2013 or OMP 
designation withdrawal date or date of withdrawal of use. Reports on consumption 
and real expenditures of these OMPs came from all health insurance companies in 
the CZ. Exchange rate of 25.4 CZK = 1 EUR was used. Results: Overall, 86 OMPs were 
authorised within the European Union (EU) between 2008 and 2013. Of these, 50 OMPs 
(58.0%) were covered from the Czech public health insurance at some point within 
this period. The number of registered OMPs increased from 54 in 2008 to 84 in 2013, 
while the number of covered OMPs doubled from 24 to 41, respectively. The annual 
public expenditure on OMPs rose simultaneously from 43 to 72 million EUR, while 
the total expenditure on drugs increased from 1.7 to 2.0 billion EUR. The OMP share of 
total pharmaceutical sales grew steadily from 2.5% in 2008, reaching 3.4% in 2011 and 
plateaued at 3.6% in 2013. Twenty-one oncological OMPs (51.2%) generated up to 72.6% 
of the overall orphan costs in 2013. ConClusions: Compared to other EU countries, 
the Czech public expenditure on OMPs of 3.6% of all drugs seems to be relatively high. 
The major part of OMP costs is in oncological diagnoses. One of the limitations is the 
exclusion of designated OMPs not authorised by EMA since these OMPs still might 
be present on the market and reimbursed. This aspect needs further investigation.
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objeCtives: The objective of this analysis was to estimate and compare the annual 
cost per patient of the administration of capsaicin 8% patch, Qutenza®, in Primary 
and Secondary Care for the treatment of adult patients with peripheral neuropathic 
pain (PNP). The annual cost per patient treated with Qutenza® was also compared 
with Pregabalin and Lidocaine in Primary Care. Methods: The costs per patient 
for each treatment were estimated by analysing the health care resources associ-
ated with the use of pregabalin, lidocaine and Qutenza®for the treatment of PNP 
from the perspective of the Spanish National Health System. Healthcare resources 
associated with the three pharmacological treatments considered were admin-
istration time and health care personnel, complementary non-pharmacological 
treatment, hospitalisation, adverse effects and concomitant medication, EUR 2013. 
Total costs per patient were estimated and compared both including and excluding 
concomitant medication to estimate the effect on the treatment costs. Results: 
The annual treatment cost per patient when Qutenza® is administrated in the hos-
pital was estimated at € 5,387.32 and € 5,259.19 when administered in Primary Care. 
Qutenza® applied in Primary Care for the treatment of PNP showed annual savings 
of € 128.14 per patient compared with the administration of Qutenza® in Secondary 
Care. Overall, the annual treatment costs per patient with pregabalin or lidocaine 
were estimated at € 14,074.14 and € 5,998.09, respectively, resulting in savings of 
€ 8,814.95 and € 738.9 respectively when compared with the annual cost per patient 
when treated with Qutenza® in Primary Care. ConClusions: The introduction 
of Qutenza® into Primary Care for the treatment of PNP is expected to result 
in annual savings due to lower administration costs associated with the use of 
Qutenza® and savings in health care personnel in Primary Care. Qutenza® also 
showed to be the less expensive option in comparison with pregabalin or lidocaine, 
independent of the area of administration.
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objeCtives: Estimate, from the Spanish National Healthcare System (SNS) perspec-
tive, the required reduction of exacerbation episodes in different patient profiles to 
maintain constant the overall treatment cost if a chronic treatment with inhaled anti-
biotics is switched to aztreonam lysine in patients with cystic fibrosis (CF) and chronic 
pulmonary infection by Pseudomonas aeruginosa (PA). Methods: A cost comparison 
model was developed considering two criteria to define patient profiles: current drug 
treatment (12 options linked to tobramycin and/or colistimethate sodium) and current 
exacerbation episodes (1-6/year). For each patient profile the overall treatment cost 
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objeCtives: To assess pill burden, health care resource utilization (HRU), and costs 
among patients with long-term immediate release (IR) hydrocodone use. Methods: 
We performed a retrospective analysis of health care claims from 2011-2012 Truven 
MarketScan® Commercial, Medicare supplemental, and Medicaid Multistate data-
bases. Patients with IR hydrocodone prescription for ≥ 90 days during 6 month 
baseline period (July 2011- December 2011) with continuous enrollment during 
baseline and 12 month follow-up periods were selected. The final population was 
sub-categorized by prescribed coverage days (PCD) of IR hydrocodone during base-
line into 90-119, 120-179, and ≥ 180 days. Chi-square or ANOVA analyses were used to 
test pill burden, HRU and costs (standardized to 2013 US dollars) during baseline and 
follow-up periods across subpopulations. Results: A total of 36,174 commercial, 
32,699 Medicaid, and 8,873 Medicare IR hydrocodone users were selected. In the 
baseline period, subgroups with longer PCD had significantly more average hydroco-
done pills per month yet fewer HRU and medical costs (all p< 0.05). However, during 
the follow-up period, groups with longer PCD had greater increase in number of 
inpatient hospitalizations and other types of HRU (length of stay, outpatient hospital 
visits, office visits, and emergency room visits). The subgroup of patients with PCD 
< 120 days had lower annual all-cause medical costs during follow-up compared 
with baseline (decreasing $2,624, $2,955, $4,209 per patient per year in Medicaid, 
Medicare and commercial patients, respectively), while patients with longer PCD 
during baseline had increased costs (p< 0.05). For example, Medicaid patients with 
120-179 PCD had an increase of $1,874 and those with ≥ 180 PCD had an increase of 
$4,348. These trends were similar for all insurance types. ConClusions: Extended 
length of PCD, particularly after 120 days, corresponds with higher patient burden 
including elevated pill burden and rising HRU and costs in both commercial and 
public insurance patients with long-term IR hydrocodone use.
PSY36
PreValence-baSed meaSurement of the economIc burden of rare 
dISeaSeS: caSe reVIew to determIne the annual coSt of acromeGalY 
In france
Ponet O.1, Tasdemir E.2, Magestro M.3, Griner B.P.4, Cummins G.5, Van Engen A.6,  
Kreeftmeijer J.6, Niemira J.4, Tao C.7
1Novartis France, Rueil Malmaison, France, 2Novartis Oncology, Origgio / VA, Italy, 3Novartis 
Pharmaceuticals Corporation, East Hanover, NJ, USA, 4Quintiles, Cambridge, MA, USA, 5Quintiles, 
Durham, NC, USA, 6Quintiles Consulting, Hoofddorp, The Netherlands, 7Quintiles Consulting, 
Cambridge, MA, USA
objeCtives: Although acromegaly is acknowledged as requiring resource-intensive 
treatment, its ultimate economic burden is unclear. As an extension of work pre-
sented at ISPOR 2013 International Conference (New Orleans, US), the objective of 
this research is to measure the annual economic burden of acromegaly in France 
using a case-review methodology with a prevalence-based sample of patients diag-
nosed with acromegaly. Methods: A case-review method was used with a sample 
of 22 endocrinologists reviewing 88 patient cases (4 cases per physician) diagnosed 
with acromegaly. The patient case histories included: resource utilization includ-
ing office visits and hospitalization, diagnostic procedures and labs, medications 
prescribed, medical procedures preformed, and an estimate of lost productivity. A 
micro-costing analysis was conducted to obtain costs in the prior 12 months for 
each patient case reviewed using published literature, medical fee schedules, and 
pharmaceutical cost databases to assign costs to treatments and medical proce-
dures identified in the survey data. Annual costs were examined across a broad 
range of patients of different ages, gender and time from diagnosis. Two biomarkers 
were used to categorize acromegaly patients as Controlled vs. Uncontrolled: Insulin 
Growth Factor-1 (IGF-1) and Growth Hormone (GH). Several patient characteristics 
were used as control factors when comparing annual economic costs: age, sex, 
and time from diagnosis. Statistical tests and confidence intervals were calcu-
lated to determine the significance of patient characteristic effects on economic 
burden. Results: Three patient subgroups were used to classify uncontrolled 
acromegaly patients: IGF-1, GH and both IGF-1 and GH. The annual per-patient 
economic burden of disease costs ranges from € 29,000 to € 79,400 across these 
groups. These cost ranges are benchmarked to other studies to provide context 
and validity. ConClusions: The total economic burden of acromegaly in France 
is significant. Understanding the factors impacting burden of illness will inform 
future improvements in treatment practice.
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objeCtives: To estimate rates of diagnosed abuse and incremental health care 
costs among long-term immediate release (IR) hydrocodone users. Methods: We 
performed a retrospective analysis of health care claims from 2011-2012 Truven 
MarketScan® Commercial and Medicaid Multistate databases. Patients with IR 
hydrocodone prescription ≥ 90 days during 6 month baseline period (July 2011- 
December 2011) with continuous enrollment during baseline and 12 month follow 
up periods were selected. Opioid abuse was defined as a patient having at least 
one medical claim indicating opioid abuse/dependency (ICD-9-CM diagnosis codes: 
304.0x, 304.7x, 305.5x, 965.00,965.02 or 965.09) during the study period. Rates of 
opioid abuse during baseline and follow up periods were estimated by plan type, 
along with total health care costs, standardized to 2013 US dollars. Generalized 
linear model regressions were used to estimate incremental costs in the post-index 
period. Results: A total of 32,699 Medicaid and 36,174 commercial IR hydrocodone 
users were selected in the study. Rates of abuse were 96 and 36 per 10,000 patients, 
respectively. Abusers had higher unadjusted annual total health care costs than 
non-abusers during both baseline and follow up period (p< 0.05). After controlling 
for baseline characteristics of age, gender, Charlson Comorbidity Index, pill burden 
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Mepact® (mifamurtide) is the first drug approved for treatment of high-grade resect-
able non-metastatic osteosarcoma in patients aged 2-30 in the last 20 years. It 
follows a randomised clinical trial showing a statistically-significant and clinically-
relevant decrease in the risk of death without compromising safety. objeCtives: 
This study assessed the cost-effectiveness and budget impact of mifamurtide added 
to the standard chemotherapy of cisplatin, doxorubicin and methotrexate with 
this same standard therapy (ST) without mifamurtide. Methods: A Markov model 
was built to combine trial-based outcomes with Spanish resource use and unit 
cost of compared options. The analysis has been carried out from the perspective 
of the Spanish National Health Service, with a time horizon of up to 60 years in 
the base analysis. A probabilistic sensitivity analysis was carried out to assess the 
influence of the uncertainty of the variables introduced into the model. All the 
costs are expressed in euros for the year 2011 and, beyond the first year, both costs 
and effects (quality-adjusted survival) have been discounted with an annual rate 
of 3%, following local recommendations. Results: The observed greater efﬁcacy 
of mifamurtide in the trial translates into a gain of 3.03 (undiscounted) and 1.33 
(discounted) QALYs and an additional cost of € 102,000. The estimated budgetary 
impact of using mifamurtide in 10% to 100% of the potential population would cost 
€ 671,000 and € 6.7 million respectively. ConClusions: The iCER of mifamurtide in 
Spain is in the low band (< € 100,000) of the iCERs obtained by other orphan drugs 
and would have a limited, predictable and affordable cost in Spain.
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objeCtives: To evaluate and compare costs of belimumab treatment plus stand-
ard of care (SoC) vs SoC alone in patients with systemic lupus erythematosus 
(SLE). Methods: The cost analysis was conducted of the belimumab treatment plus 
SoC vs SoC alone for one year. Based on the results of clinical trials to assess safety 
and efficacy of belimumab (BLISS-52 and BLISS-76) the cost structure of treatment was 
determined. Results: The costs were evaluated in the following groups: drug costs, 
costs of inpatient and outpatient visits, costs for correction of adverse events and 
costs for treating of SLE complications. The costs of inpatient visits comprised 91,830 
RUB/ 1,976 EUR for SoC alone and 52,991 RUB/ 1,140 EUR for patients treated with 
belimumab plus SoC. The correction of adverse events came to 7,763 RUB/ 167 EUR for 
SoC alone, while for belimumab plus SoC it was 7,846 RUB/ 169 EUR. The costs of treat-
ing SLE complications totaled 384,976 RUB/ 8,283 EUR and 370,229 RUB/ 7,966 EUR for 
SoC alone and belimumab plus SoC groups of patients, respectively. ConClusions: 
The costs of inpatient visits in belimumab treatment group were lower than those of 
the SoC group resulting from a reduction in the frequency of SLE flare. The costs for 
correction of adverse events were similar in both patients groups due to a good safety 
profile of belimumab. The level of costs for treating SLE complications was lower in 
belimumab as compared to that in SoC group as a consequence of lower frequency of 
cardiovascular, pulmonary, renal, and skin complications in the belimumab treatment 
group. A good safety profile and efficacy of belimumab, which had been demonstrated 
in clinical trials, led to a decrease in costs of inpatient visits and treatment of SLE 
complication in patients treated with belimumab.
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objeCtives: Opioids are the mainstay of therapy for patients with moderate to 
severe pain. Mandatory generic substitution exists in South Africa, unless other-
wise indicated by the prescriber or if the patient refuses. Few studies have been 
conducted in South Africa analysing the prescribing patterns and cost of opioid 
analgesics. Methods: A retrospective, cross-sectional drug utilisation study was 
conducted on prescription data of a medical insurance scheme administrator 
in South Africa for 2011. The database contained 2 298 312 records for medicine, 
medical devices and procedures. Results: A total of 97 491 analgesics were dis-
pensed to 31 854 patients during the year. Within ATC category N02, opioids (NO2A) 
accounted for 26.55% of analgesic prescriptions at a cost of R1 071 230.14. A total of 
9 793 patients were prescribed 25 888 opioid analgesics. The average age of patients 
was 41.50 (SD= 16.61) years. Female patients were slightly younger (average age: 
40.69 (SD= 17.05) years) than male patients (average age: 42.32 (SD= 16.09) years). 
Nine different active ingredients and two combination products were prescribed. 
Tramadol, an atypical opioid, was the most often prescribed (68.11%), followed by 
pethidine (14.39%) and morphine (8.38%). The average cost per prescription was 
R41.38 (SD= R69.29). Fentanyl had the highest average cost per prescription (R454.43), 
and pethidine the lowest (R8.53). Overall, the average cost for an originator product 
was R56.25 and for a generic product R28.95. Tramadol accounted for 68.11% of 
prescriptions and 80.40% of cost. Tramadol had the most most branded generic 
equivalents on the market (7), yet only had 42.89% generic prescribing. Most pre-
scriptions were issued by private hospitals (62.89%), followed by pharmacies (24.41%) 
and general medical practices (12.16%). Only 35.48% of the products were prescribed 
on a chronic basis. ConClusions: Tramadol dominated opioid prescribing. The 
study confirmed price differences for opioid analgesics between branded generics 
and originator products.
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